BeiGene announced that the FDA has approved its Bruton’s tyrosine kinase inhibitor, BTKi, Brukinsa for the treatment of adult patients with chronic lymphocytic leukemia, CLL, or small lymphocytic lymphoma, SLL. The U.S. approval is based on two global Phase 3 clinical trials demonstrating superior efficacy and a favorable safety profile for Brukinsa in CLL.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BGNE:
- BeiGene announces MHRA granted marketing authorization for BRUKINSA
- BeiGene announces expansion of coverage on China’s NRDL
- BeiGene presents new research from Tislelizumab program at 2023 ASCO
- BeiGene initiated with a Buy at Daiwa
- Fly Insider: Terns Pharma, Best Buy among week’s notable insider trades
